DOCSLIB.ORG

Identification of Gene 3 Ends by Automated EST Cluster Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of Gene 3 Ends by Automated EST Cluster Analysis Identification of gene 3؅ ends by automated EST cluster analysis Enrique M. Muroa,b, Robert Herringtonc, Salima Janmohamedc, Catherine Frelinc, Miguel A. Andrade-Navarroa,b,1, and Norman N. Iscovec,1,2 aOttawa Health Research Institute, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6; bMax Delbru¨ck Center for Molecular Medicine, Robert-Ro¨ssle-Strasse 10, 13125 Berlin, Germany; and cOntario Cancer Institute, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto Medical Discovery Tower, 101 College Street, Toronto, ON, Canada M5G 1L7 Edited by Tak Wah Mak, University of Toronto, Toronto, ON, Canada, and approved October 14, 2008 (received for review August 11, 2008) The properties and biology of mRNA transcripts can be affected abundance of terminal 3Ј sequences. Amplified cDNAs are profoundly by the choice of alternative polyadenylation sites, therefore ideally interrogated by probes that target sequences as .making definition of the 3؅ ends of transcripts essential for under- close to 3Ј ends as is practical standing their regulation. Here we show that 22–52% of sequences For access to 3Ј terminal sequences, biologists usually turn in commonly used human and murine ‘‘full-length’’ transcript to highly curated collections of complete mRNA sequences, databases may not currently end at bona fide polyadenylation such as the RefSeq (10), Ensembl (11), UCSC KnownGene sites. To identify probable transcript termini over the entire murine (12), FANTOM (3) and VEGA (13) collections. Probes in and human genomes, we analyzed the EST databases for positional widely used commercial microarrays are similarly selected clustering of EST ends. The analysis yielded 58,282 murine- and from sequence collections representative of full-length tran- 86,410 human-candidate polyadenylation sites, of which 75% scripts, from which probes near 3Ј polyadenylation sites could mapped to 23,091 known murine transcripts and 22,891 known be generated in principle. Affymetrix, for example, has pub- human transcripts. The murine dataset correctly predicted 97% of lished collections of murine and human transcript sequences. the 3؅ ends in a manually curated and experimentally supported However, it cannot be taken for granted that transcripts in benchmark transcript set. Of currently known genes, 15% had no public or commercial collections do in fact include sequences associated prediction and 25% had only a single predicted termi- near all used alternative sites or that a given transcript nation site. The remaining genes had an average of 3–4 alternative sequence is complete to any of its possible termini. At the polyadenylation sites predicted for each murine or human tran- present time, no survey of the extent of completeness of the script, respectively. The results are made available in the form of sequences in popular collections is available, leaving the onus tables and an interactive web site that can be mined for rapid on the user to determine whether a given transcript sequence assessment of the validity of 3؅ ends in existing collections, enu- ends at a valid polyadenylation site or not and whether other meration of potential alternative 3؅ polyadenylation sites of more frequently used sites exist upstream or downstream of known transcripts, direct retrieval of terminal sequences for design available sequence ends. of probes, and detection of polyadenylation sites not currently A useful methodology exists (14–19) for locating polyadenyl- mapped to known genes. ation sites based on the large and growing databases of EST sequences. These short sequences are sampled from larger 3Ј UTR ͉ gene prediction ͉ alternative polyadenylation ͉ transcriptome ͉ cDNA clones, which are generally reverse-transcribed from transcript probe design polyadenylated cellular transcripts after priming with oligo(dT). NCBI’s GenBank contained over 96 million such sequences as of March 2007. The high level of EST redundancy means that the he 3Ј ends of nascent mRNA transcripts are generated by a expression of each gene is described in each organism by multiple multifactorial complex that recognizes a well-defined hex- T independently derived ESTs, while their preparation based on amer polyadenylation signal (PAS, typically AAUAAA or oligo(dT) priming results in a preponderance of ESTs aligning AUUAAA) in a context that includes other less clearly defined to and terminating at 3Ј polyadenylation sites. motifs, cleaves the RNA 16–28 nt downstream of the PAS, and Here we report results directly addressing the needs of re- adds the characteristic polyA tail. Many transcripts are cleaved searchers for methodology and readily accessible databases and polyadenylated at alternative sites that may depend on Ј Ј facilitating the identification of 3 transcript ends. First, an cellular contexts (1–5). The 3 UTRs of transcripts frequently analysis of the main public murine and human transcript col- contain motifs that regulate their stability and ribosomal trans- lections provides evidence that up to half of available sequences lation (6) and their translocation to the cytoplasm. Additionally, Ј may not end at true polyadenylation sites. We further describe these 3 UTRs of transcripts may contain miRNA targets and and validate an EST-based method with improved prediction of short hairpin loops of regulatory significance. Indeed, as many candidate polyadenylation sites. The method was applied to both as 40% of miRNA targets have been estimated to be located in Ј Ј murine and human genomes to yield sets of predicted 3 ends alternative 3 UTR segments (7). The properties and biology of mapped against the currently known genes. The results are transcripts can therefore be affected profoundly by the choice of alternative polyadenylation sites, making definition of the 3Ј ends of transcripts essential for understanding their regulation. Author contributions: E.M.M., M.A.A.-N., and N.N.I. designed research; E.M.M., R.H., S.J., There are additional practical motivations for determining 3Ј and C.F. performed research; M.A.A.-N. and N.N.I. analyzed data; and M.A.A.-N. and N.N.I. ends. For many genes, similarities in coding regions may make wrote the paper. it necessary to find probes that target the UTRs to achieve the The authors declare no conflict of interest. desired specificity. Furthermore, methods for amplification of This article is a PNAS Direct Submission. cDNA are finding increasing use in circumstances wherein 1M.A.A.-N and N.N.I. contributed equally to this work. amounts of available RNA are too small, for example, for direct 2To whom correspondence should be addressed. E-mail: [email protected]. application to microarrays (8, 9). Because amplification proto- This article contains supporting information online at www.pnas.org/cgi/content/full/ cols are typically initiated by oligo(dT) priming on transcript 0807813105/DCSupplemental. polyA tails, there is an inherent bias toward best preservation of © 2008 by The National Academy of Sciences of the USA 20286–20290 ͉ PNAS ͉ December 23, 2008 ͉ vol. 105 ͉ no. 51 www.pnas.org͞cgi͞doi͞10.1073͞pnas.0807813105 Downloaded by guest on September 30, 2021 Table 1. Proportions of transcript sequence collections tively low accuracy of EST sequencing and recent genomic containing a 3؅ PAS duplications, some ESTs can be aligned with more than one Proportion genomic position. To avoid possible misidentifications, ambig- No. of with uously aligning ESTs were excluded from our analysis. For Collection transcripts terminal PAS end-cluster detection, we plotted the number of matching ESTs against position along the entire genome. This analysis revealed, Mouse as expected, that the numbers of aligned ESTs gradually increase RefSeq mm6 Total NM࿝* 18,280 0.74 toward transcript 3Ј ends (Fig. 1) and then abruptly fall, sug- Ensembl 36.40 Known 28,110 0.56 gesting that the plot could be used to infer the direction of Ensembl 36.40 Novel 3,192 0.14 transcription. We used an approach that exploited a convolution Affymetrix MOE430 Consensus 45,037 0.58 algorithm to detect and quantify the shape of such edges, FANTOM3 Representative 46,315 0.58 allowing adjustment of the algorithm parameters. We then tuned VEGA Known July 2007 24,791 0.48 parameters and detection thresholds on various transcript col- UCSC KnownGenes mm9 43,685 0.64 lections to optimize the relationship between the numbers of Human database sequence ends detected and the proportion of pre- ࿝ RefSeq Release 20 human NM * 24,162 0.78 dicted ends corresponding to nominal ends. Fig. S3 illustrates Affymetrix HG-U133 Consensus/Exemplar 54,613 0.54 optimization of 1 parameter, the minimum number of EST ends VEGA Total October 2006 98,630 0.60 required to identify a potential polyadenylation site. H-InvDB v3.8 Representative 35,005 0.60 The automated analysis identified 58,282 and 86,410 EST UCSC KnownGenes hg18 54,896 0.73 clusters on the murine and human genomes, respectively, that The presence of a validated PAS (Table S1 and Fig. S1) within 40 nt of the contain at least 2 EST ends and an appropriately positioned transcript ends was recorded after trimming of extraneous or homopoly- PAS. These candidate 3Ј ends were mapped in relationship to the meric sequences from the 3Ј ends as required for individual datasets. The UCSC KnownGene (12) collection and assembled in Dataset S1, VEGA (13) and H-InvDB (www.h-invitational.jp) (23) collections are highly Dataset S2, Dataset S3, and Dataset S4. The legends to the curated. VEGA integrates gene information for vertebrate organisms datasets are located at the end of the Supplementary Text. originating from NCBI, UCSC, Ensembl, and the Sanger Institute. H-InvDB Approximately 75% of candidate ends lay within KnownGene integrates and maps cDNAs to the human genome from selected high- throughput cDNA sequencing projects. Source files for the analysis were transcription zones or up to 10 kb downstream of their nominal RefSeq (mm6) refMrna.fa; Ensembl Mus࿝musculus.NCBIM36.40.cdna.known.fa ends.
Load more

Recommended publications
  • Functional T Cells Phosphodiesterase 7A-Deficient Mice Have
    Phosphodiesterase 7A-Deficient Mice Have Functional T Cells Guchen Yang, Kim W. McIntyre, Robert M. Townsend, Henry H. Shen, William J. Pitts, John H. Dodd, Steven G. This information is current as Nadler, Murray McKinnon and Andrew J. Watson of October 2, 2021. J Immunol 2003; 171:6414-6420; ; doi: 10.4049/jimmunol.171.12.6414 http://www.jimmunol.org/content/171/12/6414 Downloaded from References This article cites 37 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/171/12/6414.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 2, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Phosphodiesterase 7A-Deficient Mice Have Functional T Cells Guchen Yang,1 Kim W. McIntyre, Robert M. Townsend, Henry H. Shen, William J. Pitts, John H. Dodd, Steven G. Nadler, Murray McKinnon, and Andrew J.
    [Show full text]
  • Inhibiting PDE7A Enhances the Protective Effects of Neural Stem
    Research Article: New Research | Cognition and Behavior Inhibiting PDE7A enhances the protective effects of neural stem cells on neurodegeneration and memory deficits in sevoflurane-exposed mice https://doi.org/10.1523/ENEURO.0071-21.2021 Cite as: eNeuro 2021; 10.1523/ENEURO.0071-21.2021 Received: 19 February 2021 Revised: 21 May 2021 Accepted: 25 May 2021 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2021 Huang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. 1 Inhibiting PDE7A enhances the protective effects of neural stem cells on 2 neurodegeneration and memory deficits in sevoflurane-exposed mice 3 Yanfang Huang, Yingle Chen*, Zhenming Kang, Shunyuan Li* 4 Department of Anesthesiology, Quanzhou First Hospital Affiliated to Fujian Medical 5 University, Quanzhou 362000, Fujian, China 6 7 *Corresponding authors 8 Shunyuan Li and Yingle Chen 9 Department of Anesthesiology, Quanzhou First Hospital Affiliated to Fujian Medical 10 University, Quanzhou 362000, Fujian, China 11 Email: [email protected] (Shunyuan Li); [email protected] (Yingle Chen) 12 Tel: 86-18960333666 13 14 15 Running title: Role of PDE7A in neurodegeneration 16 17 1 18 Abstract 19 Sevoflurane is widely used in general anesthesia, especially for children.
    [Show full text]
  • Number 2 February 2014
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST -CNRS Volume 18 - Number 2 February 2014 The PDF version of the Atlas of Genetics and Cytogenetics in Oncology and Haematology is a reissue of the original articles published in collaboration with the Institute for Scientific and Technical Information (INstitut de l’Information Scientifique et Technique - INIST) of the French National Center for Scientific Research (CNRS) on its electronic publishing platform I-Revues. Online and PDF versions of the Atlas of Genetics and Cytogenetics in Oncology and Haematology are hosted by INIST-CNRS. Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST -CNRS Scope The Atlas of Genetics and Cytogenetics in Oncology and Haematology is a peer reviewed on-line journal in open access, devoted to genes, cytogenetics, and clinical entities in cancer, and cancer-prone diseases. It presents structured review articles (“cards”) on genes, leukaemias, solid tumours, cancer-prone diseases, and also more traditional review articles (“deep insights”) on the above subjects and on surrounding topics. It also present case reports in hematology and educational items in the various related topics for students in Medicine and in Sciences. Editorial correspondance Jean-Loup Huret Genetics, Department of Medical Information, University Hospital F-86021 Poitiers, France tel +33 5 49 44 45 46 or +33 5 49 45 47 67 [email protected] or [email protected] Staff Mohammad Ahmad, Mélanie Arsaban, Marie-Christine Jacquemot-Perbal, Vanessa Le Berre, Anne Malo, Carol Moreau, Catherine Morel-Pair, Laurent Rassinoux, Alain Zasadzinski. Philippe Dessen is the Database Director, and Alain Bernheim the Chairman of the on-line version (Gustave Roussy Institute – Villejuif – France).
    [Show full text]
  • Mechanisms of Action of PDE5 Inhibition in Erectile Dysfunction
    International Journal of Impotence Research (2004) 16, S4–S7 & 2004 Nature Publishing Group All rights reserved 0955-9930/04 $30.00 www.nature.com/ijir Original Research Mechanisms of action of PDE5 inhibition in erectile dysfunction JD Corbin1* 1Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennesse, USA A spinal reflex and the L-arginine–nitric oxide–guanylyl cyclase–cyclic guanosine monophosphate (cGMP) pathway mediate smooth muscle relaxation that results in penile erection. Nerves and endothelial cells directly release nitric oxide in the penis, where it stimulates guanylyl cyclase to produce cGMP and lowers intracellular calcium levels. This triggers relaxation of arterial and trabecular smooth muscle, leading to arterial dilatation, venous constriction, and erection. Phosphodiesterase 5 (PDE5) is the predominant phosphodiesterase in the corpus cavernosum. The catalytic site of PDE5 normally degrades cGMP, and PDE5 inhibitors such as sildenafil potentiate endogenous increases in cGMP by inhibiting its breakdown at the catalytic site. Phosphorylation of PDE5 increases its enzymatic activity as well as the affinity of its allosteric (noncatalytic/GAF domains) sites for cGMP. Binding of cGMP to the allosteric site further stimulates enzymatic activity. Thus phosphorylation of PDE5 and binding of cGMP to the noncatalytic sites mediate negative feedback regulation of the cGMP pathway. International Journal of Impotence Research (2004) 16, S4–S7. doi:10.1038/sj.ijir.3901205 Keywords: phosphodiesterase inhibitors; vasodilator agents; cyclic GMP; impotence; penile erection Introduction the tone of penile vasculature and the smooth muscle of the corpus cavernosum. In primates, including humans, the L-arginine– In recent years, a deeper understanding of the nitric oxide–guanylyl cyclase–cyclic guanosine regulation of penile smooth muscle has led to monophosphate (cGMP) pathway is the key me- greater insight into the physiology of normal erectile chanism of penile erection1–4 (Figure 1).
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Supplementary Table S2
    1-high in cerebrotropic Gene P-value patients Definition BCHE 2.00E-04 1 Butyrylcholinesterase PLCB2 2.00E-04 -1 Phospholipase C, beta 2 SF3B1 2.00E-04 -1 Splicing factor 3b, subunit 1 BCHE 0.00022 1 Butyrylcholinesterase ZNF721 0.00028 -1 Zinc finger protein 721 GNAI1 0.00044 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 GNAI1 0.00049 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 PDE1B 0.00069 -1 Phosphodiesterase 1B, calmodulin-dependent MCOLN2 0.00085 -1 Mucolipin 2 PGCP 0.00116 1 Plasma glutamate carboxypeptidase TMX4 0.00116 1 Thioredoxin-related transmembrane protein 4 C10orf11 0.00142 1 Chromosome 10 open reading frame 11 TRIM14 0.00156 -1 Tripartite motif-containing 14 APOBEC3D 0.00173 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D ANXA6 0.00185 -1 Annexin A6 NOS3 0.00209 -1 Nitric oxide synthase 3 SELI 0.00209 -1 Selenoprotein I NYNRIN 0.0023 -1 NYN domain and retroviral integrase containing ANKFY1 0.00253 -1 Ankyrin repeat and FYVE domain containing 1 APOBEC3F 0.00278 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F EBI2 0.00278 -1 Epstein-Barr virus induced gene 2 ETHE1 0.00278 1 Ethylmalonic encephalopathy 1 PDE7A 0.00278 -1 Phosphodiesterase 7A HLA-DOA 0.00305 -1 Major histocompatibility complex, class II, DO alpha SOX13 0.00305 1 SRY (sex determining region Y)-box 13 ABHD2 3.34E-03 1 Abhydrolase domain containing 2 MOCS2 0.00334 1 Molybdenum cofactor synthesis 2 TTLL6 0.00365 -1 Tubulin tyrosine ligase-like family, member 6 SHANK3 0.00394 -1 SH3 and multiple ankyrin repeat domains 3 ADCY4 0.004 -1 Adenylate cyclase 4 CD3D 0.004 -1 CD3d molecule, delta (CD3-TCR complex) (CD3D), transcript variant 1, mRNA.
    [Show full text]
  • PDE7A, Active PDE7A, Active
    Catalog # Aliquot Size P95-31G -05 5 µg P95-31G -10 10 µg PDE7A, Active Human recombinant protein expressed in Sf9 cells Catalog # P95-31G Lot # F723 -2 Product Description Specific Activity Recombinant human PDE7A (104-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. The gene accession number is NM_002603 . 2,400,000 Gene Aliases 1,800,000 1,200,000 HCP1; PDE7 600,000 Formulation (RLU) Activity 0 5 10 15 20 Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM Protein (ng) DTT, 0.1mM PMSF, 25% glycerol. The specific activity of PDE7A was determined to be 160 nmol /min/mg as per activity assay protocol. Storage and Stability Purity o Store product at –70 C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. The purity of PDE7A was Scientific Background determined to be >90% by densitometry. PDE7A is a member of the phosphodiesterase family of Approx. MW 64kDa . proteins that play a critical role in regulating intracellular levels of cAMP and cGMP. PDE7A is a high-affinity cAMP-specific PDE and is expressed in T cell lines, peripheral blood T lymphocytes, epithelial cell lines, airway and vascular smooth muscle cells, lung fibroblasts, and eosinophils. PDE7 plays a critical role in PDE7A, Active the regulation of human T cell function and selective Human recombinant protein expressed in Sf9 cells PDE7 inhibitors are being examined to treat immunological and inflammatory disorders (1).
    [Show full text]
  • Oligonucleotide Compositions and Methods for Treating Disease Including Inflammatory Conditions
    (19) & (11) EP 2 314 595 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.04.2011 Bulletin 2011/17 C07H 21/00 (2006.01) C12N 15/11 (2006.01) A61K 31/7088 (2006.01) A61P 29/00 (2006.01) (21) Application number: 10183977.7 (22) Date of filing: 29.09.2004 (84) Designated Contracting States: • Zemzoumi, Khalid AT BE BG CH CY CZ DE DK EE ES FI FR GB GR MONTREAL Québec H2H 1V3 (CA) HU IE IT LI LU MC NL PL PT RO SE SI SK TR • D’Anjou, Hélène BROSSARD Québec J4X 2W5 (CA) (30) Priority: 29.09.2003 US 507016 P (74) Representative: Cabinet Plasseraud (62) Document number(s) of the earlier application(s) in 52, rue de la Victoire accordance with Art. 76 EPC: 75440 Paris Cedex 09 (FR) 04786683.5 / 1 668 024 Remarks: (71) Applicant: Topigen Pharmaceuticals Inc. This application was filed on 30-09-2010 as a Montréal, QC H1W 4A4 (CA) divisional application to the application mentioned under INID code 62. (72) Inventors: • Renzi, Paolo WESTMOUNT Québec H3Y 1E9 (CA) (54) Oligonucleotide compositions and methods for treating disease including inflammatory conditions (57) The invention relates to therapeutic antisense structive pulmonary disease (COPD), acute respiratory oligonucleotides directed against genes coding for phos- distress syndrome, bronchitis, chronic bronchitis, silico- phodiesterase (PDEs) and the use of these in combina- sis, pulmonary fibrosis, lung allograft rejection, allergic tion. These antisense oligonucleotides may be used as rhinitis and chronic sinusitis as well as other conditions analytical tools and/or as therapeutic agents in the treat- in which an increase in cyclic AMP or a decrease in PDE ment of disease associated with reduced cellular cAMP levels is beneficial in a patient, such as inflammatory diseases of the respi- ratory tract including, for example, asthma, chronic ob- EP 2 314 595 A2 Printed by Jouve, 75001 PARIS (FR) EP 2 314 595 A2 Description Field of the Invention 5 [0001] The invention relates to methods, reagents and compositions of use for antisense oligonucleotide-based ther- apy.
    [Show full text]
  • Whole Genome Sequencing of Familial Non-Medullary Thyroid Cancer Identifies Germline Alterations in MAPK/ERK and PI3K/AKT Signaling Pathways
    biomolecules Article Whole Genome Sequencing of Familial Non-Medullary Thyroid Cancer Identifies Germline Alterations in MAPK/ERK and PI3K/AKT Signaling Pathways Aayushi Srivastava 1,2,3,4 , Abhishek Kumar 1,5,6 , Sara Giangiobbe 1, Elena Bonora 7, Kari Hemminki 1, Asta Försti 1,2,3 and Obul Reddy Bandapalli 1,2,3,* 1 Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany; [email protected] (A.S.); [email protected] (A.K.); [email protected] (S.G.); [email protected] (K.H.); [email protected] (A.F.) 2 Hopp Children’s Cancer Center (KiTZ), D-69120 Heidelberg, Germany 3 Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), D-69120 Heidelberg, Germany 4 Medical Faculty, Heidelberg University, D-69120 Heidelberg, Germany 5 Institute of Bioinformatics, International Technology Park, Bangalore 560066, India 6 Manipal Academy of Higher Education (MAHE), Manipal, Karnataka 576104, India 7 S.Orsola-Malphigi Hospital, Unit of Medical Genetics, 40138 Bologna, Italy; [email protected] * Correspondence: [email protected]; Tel.: +49-6221-42-1709 Received: 29 August 2019; Accepted: 10 October 2019; Published: 13 October 2019 Abstract: Evidence of familial inheritance in non-medullary thyroid cancer (NMTC) has accumulated over the last few decades. However, known variants account for a very small percentage of the genetic burden. Here, we focused on the identification of common pathways and networks enriched in NMTC families to better understand its pathogenesis with the final aim of identifying one novel high/moderate-penetrance germline predisposition variant segregating with the disease in each studied family.
    [Show full text]
  • Supp Table 6.Pdf
    Supplementary Table 6. Processes associated to the 2037 SCL candidate target genes ID Symbol Entrez Gene Name Process NM_178114 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion NM_033474 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome adhesion NM_027060 BTBD9 BTB (POZ) domain containing 9 adhesion NM_001039149 CD226 CD226 molecule adhesion NM_010581 CD47 CD47 molecule adhesion NM_023370 CDH23 cadherin-like 23 adhesion NM_207298 CERCAM cerebral endothelial cell adhesion molecule adhesion NM_021719 CLDN15 claudin 15 adhesion NM_009902 CLDN3 claudin 3 adhesion NM_008779 CNTN3 contactin 3 (plasmacytoma associated) adhesion NM_015734 COL5A1 collagen, type V, alpha 1 adhesion NM_007803 CTTN cortactin adhesion NM_009142 CX3CL1 chemokine (C-X3-C motif) ligand 1 adhesion NM_031174 DSCAM Down syndrome cell adhesion molecule adhesion NM_145158 EMILIN2 elastin microfibril interfacer 2 adhesion NM_001081286 FAT1 FAT tumor suppressor homolog 1 (Drosophila) adhesion NM_001080814 FAT3 FAT tumor suppressor homolog 3 (Drosophila) adhesion NM_153795 FERMT3 fermitin family homolog 3 (Drosophila) adhesion NM_010494 ICAM2 intercellular adhesion molecule 2 adhesion NM_023892 ICAM4 (includes EG:3386) intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)adhesion NM_001001979 MEGF10 multiple EGF-like-domains 10 adhesion NM_172522 MEGF11 multiple EGF-like-domains 11 adhesion NM_010739 MUC13 mucin 13, cell surface associated adhesion NM_013610 NINJ1 ninjurin 1 adhesion NM_016718 NINJ2 ninjurin 2 adhesion NM_172932 NLGN3 neuroligin
    [Show full text]
  • Mouse Ttc39a Knockout Project (CRISPR/Cas9)
    https://www.alphaknockout.com Mouse Ttc39a Knockout Project (CRISPR/Cas9) Objective: To create a Ttc39a knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Ttc39a gene (NCBI Reference Sequence: NM_153392 ; Ensembl: ENSMUSG00000028555 ) is located on Mouse chromosome 4. 18 exons are identified, with the ATG start codon in exon 1 and the TAG stop codon in exon 18 (Transcript: ENSMUST00000064129). Exon 2~5 will be selected as target site. Cas9 and gRNA will be co-injected into fertilized eggs for KO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 2 starts from about 2.26% of the coding region. Exon 2~5 covers 22.11% of the coding region. The size of effective KO region: ~6956 bp. The KO region does not have any other known gene. Page 1 of 9 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 3 4 5 18 Legends Exon of mouse Ttc39a Knockout region Page 2 of 9 https://www.alphaknockout.com Overview of the Dot Plot (up) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section upstream of Exon 2 is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. The gRNA site is selected outside of these tandem repeats. Overview of the Dot Plot (down) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section downstream of Exon 5 is aligned with itself to determine if there are tandem repeats.
    [Show full text]
  • Mouse Ttc39a Conditional Knockout Project (CRISPR/Cas9)
    https://www.alphaknockout.com Mouse Ttc39a Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Ttc39a conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Ttc39a gene (NCBI Reference Sequence: NM_153392 ; Ensembl: ENSMUSG00000028555 ) is located on Mouse chromosome 4. 18 exons are identified, with the ATG start codon in exon 1 and the TAG stop codon in exon 18 (Transcript: ENSMUST00000064129). Exon 3~5 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Ttc39a gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-110F24 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 3 starts from about 8.33% of the coding region. The knockout of Exon 3~5 will result in frameshift of the gene. The size of intron 2 for 5'-loxP site insertion: 5201 bp, and the size of intron 5 for 3'-loxP site insertion: 3358 bp. The size of effective cKO region: ~2297 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 3 4 5 18 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Ttc39a Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats.
    [Show full text]